JPH01299230A - ピロキシカムの医薬組成物水溶液およびその製造方法 - Google Patents
ピロキシカムの医薬組成物水溶液およびその製造方法Info
- Publication number
- JPH01299230A JPH01299230A JP1077949A JP7794989A JPH01299230A JP H01299230 A JPH01299230 A JP H01299230A JP 1077949 A JP1077949 A JP 1077949A JP 7794989 A JP7794989 A JP 7794989A JP H01299230 A JPH01299230 A JP H01299230A
- Authority
- JP
- Japan
- Prior art keywords
- piroxicam
- aqueous solution
- active ingredient
- pharmaceutical composition
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960002702 piroxicam Drugs 0.000 title claims abstract description 28
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title description 9
- 239000000243 solution Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 17
- 238000002347 injection Methods 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000012153 distilled water Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 3
- 239000000203 mixture Substances 0.000 description 26
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 7
- 108010042126 Creatine kinase Proteins 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007972 injectable composition Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- -1 alkali metal salt Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 206010017931 gastrointestinal anthrax Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8820073A IT1216686B (it) | 1988-04-01 | 1988-04-01 | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
| IT20073A/88 | 1988-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01299230A true JPH01299230A (ja) | 1989-12-04 |
Family
ID=11163585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1077949A Pending JPH01299230A (ja) | 1988-04-01 | 1989-03-29 | ピロキシカムの医薬組成物水溶液およびその製造方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4942167A (it) |
| EP (1) | EP0336200B1 (it) |
| JP (1) | JPH01299230A (it) |
| KR (1) | KR890015745A (it) |
| AT (1) | ATE85757T1 (it) |
| AU (1) | AU608142B2 (it) |
| CA (1) | CA1321352C (it) |
| DE (2) | DE336200T1 (it) |
| DK (1) | DK157689A (it) |
| ES (1) | ES2011232T3 (it) |
| FI (1) | FI90202C (it) |
| GR (2) | GR890300196T1 (it) |
| IE (1) | IE63714B1 (it) |
| IT (1) | IT1216686B (it) |
| MA (1) | MA21527A1 (it) |
| NO (1) | NO175406C (it) |
| NZ (1) | NZ228576A (it) |
| PT (1) | PT90124B (it) |
| ZA (1) | ZA892399B (it) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998001139A1 (en) * | 1996-07-03 | 1998-01-15 | Eisai Co., Ltd. | Injections containing lipid a analogues and process for the preparation thereof |
| JP2003535902A (ja) * | 2000-06-20 | 2003-12-02 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定な高濃度メロキシカム溶液 |
| JP2005511720A (ja) * | 2001-12-12 | 2005-04-28 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 無針注射用の安定な高濃度メロキシカム溶液 |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US9993557B2 (en) | 2000-06-20 | 2018-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
| US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1241088B (it) * | 1990-03-27 | 1993-12-29 | Chiesi Farma Spa | Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche |
| HU205550B (en) * | 1990-11-27 | 1992-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pyroxycam solution of increased stability, free from effects damaging tussues |
| US5362758A (en) * | 1992-09-18 | 1994-11-08 | Pfizer Inc. | Ophthalmic piroxicam solution |
| US5420124A (en) * | 1994-01-12 | 1995-05-30 | Kim; Young S. | Stable, painless piroxicam potassium injectable composition |
| CN1047077C (zh) * | 1994-01-15 | 1999-12-08 | 金元圭 | 稳定、无痛的吡罗昔康钾可注射组合物 |
| US5807568A (en) * | 1994-12-27 | 1998-09-15 | Mcneil-Ppc, Inc. | Enhanced delivery of topical compositions containing flurbiprofen |
| IT1283252B1 (it) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | Soluzioni di piroxicam iniettabili per via parenterale |
| US8992980B2 (en) * | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| ES2381672T3 (es) | 2003-11-14 | 2012-05-30 | Senju Pharmaceutical Co., Ltd. | Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco |
| DE102004021281A1 (de) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
| EP1942902A1 (en) * | 2005-09-30 | 2008-07-16 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical preparation containing meloxicam |
| JP5559339B2 (ja) | 2009-10-12 | 2014-07-23 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | メロキシカムを含む組成物のための容器 |
| BR112012022073A2 (pt) | 2010-03-03 | 2017-10-31 | Boehringer Ingelheim Vetmedica Gmbh | uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos. |
| US20110218191A1 (en) * | 2010-03-03 | 2011-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long term-treatment of kidney disorders in cats |
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| US20220142925A1 (en) * | 2019-03-01 | 2022-05-12 | Eurofarma Laboratórios S.A. | Non-steroidal anti-inflammatory lyophilized pharmaceutical composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE421792B (sv) * | 1976-01-12 | 1982-02-01 | Pfizer | Forfarande for framstellning av n-(2-pyridyl)-4-hydroxi-2-metyl-2h-1,2-benso-tiazin-3-karboxamid-1,1-dioxid |
-
1988
- 1988-04-01 IT IT8820073A patent/IT1216686B/it active Protection Beyond IP Right Term
-
1989
- 1989-03-21 EP EP89105004A patent/EP0336200B1/en not_active Expired - Lifetime
- 1989-03-21 DE DE198989105004T patent/DE336200T1/de active Pending
- 1989-03-21 ES ES89105004T patent/ES2011232T3/es not_active Expired - Lifetime
- 1989-03-21 DE DE8989105004T patent/DE68904922T2/de not_active Expired - Fee Related
- 1989-03-21 AT AT89105004T patent/ATE85757T1/de not_active IP Right Cessation
- 1989-03-28 MA MA21773A patent/MA21527A1/fr unknown
- 1989-03-28 PT PT90124A patent/PT90124B/pt not_active IP Right Cessation
- 1989-03-29 JP JP1077949A patent/JPH01299230A/ja active Pending
- 1989-03-31 KR KR1019890004209A patent/KR890015745A/ko active IP Right Grant
- 1989-03-31 IE IE103289A patent/IE63714B1/en not_active IP Right Cessation
- 1989-03-31 FI FI891570A patent/FI90202C/fi not_active IP Right Cessation
- 1989-03-31 CA CA000595421A patent/CA1321352C/en not_active Expired - Fee Related
- 1989-03-31 DK DK157689A patent/DK157689A/da not_active IP Right Cessation
- 1989-03-31 AU AU32297/89A patent/AU608142B2/en not_active Ceased
- 1989-03-31 NZ NZ228576A patent/NZ228576A/en unknown
- 1989-03-31 NO NO891367A patent/NO175406C/no unknown
- 1989-03-31 US US07/331,457 patent/US4942167A/en not_active Expired - Fee Related
- 1989-03-31 ZA ZA892399A patent/ZA892399B/xx unknown
-
1990
- 1990-11-29 GR GR89300196T patent/GR890300196T1/el unknown
-
1993
- 1993-02-18 GR GR930400298T patent/GR3007107T3/el unknown
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998001139A1 (en) * | 1996-07-03 | 1998-01-15 | Eisai Co., Ltd. | Injections containing lipid a analogues and process for the preparation thereof |
| US6235724B1 (en) | 1996-07-03 | 2001-05-22 | Eisai Co., Ltd. | Injections containing lipid a analogues and process for the preparation thereof |
| JP2003535902A (ja) * | 2000-06-20 | 2003-12-02 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定な高濃度メロキシカム溶液 |
| US9993557B2 (en) | 2000-06-20 | 2018-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions |
| JP2005511720A (ja) * | 2001-12-12 | 2005-04-28 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 無針注射用の安定な高濃度メロキシカム溶液 |
| US10098891B2 (en) | 2001-12-12 | 2018-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Highly concentrated stable meloxicam solutions for needleless injection |
| US10548901B2 (en) | 2004-02-23 | 2020-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Meloxicam for the treatment of respiratory diseases in pigs |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| US9943486B2 (en) | 2010-05-05 | 2018-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
Also Published As
| Publication number | Publication date |
|---|---|
| AU608142B2 (en) | 1991-03-21 |
| NZ228576A (en) | 1990-10-26 |
| IT1216686B (it) | 1990-03-08 |
| GR890300196T1 (en) | 1990-11-29 |
| CA1321352C (en) | 1993-08-17 |
| IE891032L (en) | 1989-10-01 |
| DE336200T1 (de) | 1990-03-01 |
| EP0336200A1 (en) | 1989-10-11 |
| ES2011232A4 (es) | 1990-01-01 |
| US4942167A (en) | 1990-07-17 |
| PT90124B (pt) | 1994-06-30 |
| PT90124A (pt) | 1989-11-10 |
| ES2011232T3 (es) | 1994-01-16 |
| FI891570A0 (fi) | 1989-03-31 |
| DE68904922D1 (de) | 1993-03-25 |
| NO891367L (no) | 1989-10-02 |
| FI891570A (fi) | 1989-10-02 |
| DE68904922T2 (de) | 1993-06-03 |
| IT8820073A0 (it) | 1988-04-01 |
| ATE85757T1 (de) | 1993-03-15 |
| NO891367D0 (no) | 1989-03-31 |
| GR3007107T3 (it) | 1993-07-30 |
| FI90202C (fi) | 1994-01-10 |
| NO175406B (no) | 1994-07-04 |
| NO175406C (no) | 1994-10-12 |
| KR890015745A (ko) | 1989-11-25 |
| ZA892399B (en) | 1989-11-29 |
| MA21527A1 (fr) | 1989-10-01 |
| AU3229789A (en) | 1989-10-05 |
| DK157689D0 (da) | 1989-03-31 |
| EP0336200B1 (en) | 1993-02-17 |
| DK157689A (da) | 1989-10-02 |
| IE63714B1 (en) | 1995-05-31 |
| FI90202B (fi) | 1993-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01299230A (ja) | ピロキシカムの医薬組成物水溶液およびその製造方法 | |
| RU2481842C2 (ru) | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций | |
| JP2769253B2 (ja) | 水性液剤 | |
| KR100851679B1 (ko) | 2-(4-이소부틸페닐)프로피온산의 약학 조성물 | |
| CA2598503C (fr) | Nouvelles compositions ophtalmologiques et leur mode d'utilisation | |
| JPH07116029B2 (ja) | トラニラスト水溶液製剤 | |
| KR20010012521A (ko) | 방부 조성물 | |
| JP2002509875A (ja) | 経口活性剤懸濁液 | |
| AU2002224475A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
| US20030100612A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
| JP2808378B2 (ja) | 水性懸濁液剤の製造法 | |
| JPS58174309A (ja) | 消炎点眼剤 | |
| JP5434981B2 (ja) | 点眼剤 | |
| JPH03109326A (ja) | フレロキサシン点眼液 | |
| WO1992017174A1 (en) | Process for preparing aqueous suspension | |
| JPH02193931A (ja) | 角膜疾患治療用点眼剤 | |
| CA2133805A1 (en) | Composition for prophylaxis and treatment of myopia | |
| WO1993023032A1 (en) | Remedy for cataract and production thereof | |
| JP2001172183A (ja) | 眼科用医薬組成物 | |
| JP4961671B2 (ja) | 点眼剤 | |
| JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
| JP2003081846A (ja) | 液状鎮咳去痰薬 | |
| JPH04501563A (ja) | 水溶性イボパミン酸付加塩を含有する眼薬 | |
| JP2005247796A (ja) | 点眼剤 | |
| CN116847826A (zh) | 包含左氧氟沙星和酮咯酸的眼用组合物、其制备方法和用途 |